Amwins Group Benefits works with brokers to help their clients navigate the future of gene therapy by empowering them to implement smart, practical and complete risk-management programs and strategies. We bring unrivaled knowledge and expertise to our retail partners by providing meaningful solutions that protect employers as they face the ever-evolving and complex gene-therapy landscape.
Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for treating or curing disease. According to the FDA, there are 30+ cellular and gene therapies in the market today and seven to 10 additional approved treatments predicted by next year. Current treatment costs range between $338,000 and $4,250,000 and are expected to continue to rise as more approved gene-therapy treatments hit the market.
The Amwins Gene Therapy Solutions program currently provides coverage for Food and Drug Administration (FDA) approved treatments that deliver curative or life-altering solutions for hereditary blindness and spinal muscular atrophy: